SOURCE: National Institute of General Medical Sciences (NIGMS)
DATE: March 1, 2007
EXCERPTS: "In the future, doctors may be able to prescribe the right dose of the right medicine the first time for everyone [including women]. This would mean that patients receive medicines that are safer and more effective for them, speeding recovery and reducing adverse drug reactions (estimated at 100,000 deaths and 2 million hospitalizations annually in the United States1). In this way, taking individual genetic profiles into account when developing and prescribing medicines would lead to better health care overall.
This echoes the vision of Health and Human Services Secretary Michael O. Leavitt, who states in his 500-Day Plan2 that he foresees “a nation in which…medications are safer and more effective because they are chosen based on the patient’s personal characteristics.”"
....
"NIH launched the Pharmacogenetics Research Network (PGRN), a nationwide collaboration of hundreds of scientists focused on understanding how genes affect the way a person responds to medicines. Since its inception, PGRN scientists have studied genes and medications relevant to a wide range of diseases, including asthma, depression, cancer, and heart disease. A key component of the PGRN is the Pharmacogenetics Knowledge Base, an online resource that contains pharmacogenetic data from the PGRN and others, and is freely available to the research community.
The PGRN was launched with grants totaling $140 million over 5 years. An additional $150 million is allocated for the period of 2005-2009. The PGRN is funded largely through the National Institute of General Medical Sciences and the National Heart, Lung, and Blood Institute, with additional support from the National Cancer Institute, the National Library of Medicine, the National Institute of Environmental Health Sciences, The National Institute on Drug Abuse, the National Institute of Mental Health, the National Human Genome Research Institute, and the Office of Research on Women’s Health." more